Sensei Biotherapeutics Inc (SNSE)

$0.6044

-0.03

(-5.31%)

Market is closed - opens 7 PM, 18 Jun 2024

Insights on Sensei Biotherapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 76.7% return, outperforming this stock by 129.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 244.3% return, outperforming this stock by 339.2%

Performance

  • $0.60
    $0.66
    $0.60
    downward going graph

    0.0%

    Downside

    Day's Volatility :8.66%

    Upside

    8.66%

    downward going graph
  • $0.51
    $1.94
    $0.60
    downward going graph

    15.0%

    Downside

    52 Weeks Volatility :73.71%

    Upside

    69.07%

    downward going graph

Returns

PeriodSensei Biotherapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-39.5%
0.4%
0.0%
6 Months
2.95%
8.7%
0.0%
1 Year
-52.72%
10.3%
0.0%
3 Years
-94.95%
16.5%
-22.7%

Highlights

Market Capitalization
15.6M
Book Value
$2.33
Earnings Per Share (EPS)
-1.21
Wall Street Target Price
4.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-24.83%
Return On Equity TTM
-41.63%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-33.4M
Diluted Eps TTM
-1.21
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.12
EPS Estimate Next Year
-1.14
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.24

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Sensei Biotherapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 603.18%

Current $0.60
Target $4.25

Technicals Summary

Sell

Neutral

Buy

Sensei Biotherapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Sensei Biotherapeutics Inc
Sensei Biotherapeutics Inc
-58.28%
2.95%
-52.72%
-94.95%
-96.62%
Moderna, Inc.
Moderna, Inc.
5.36%
63.93%
12.72%
-30.84%
787.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.52%
21.82%
32.68%
93.38%
233.31%
Novo Nordisk A/s
Novo Nordisk A/s
8.04%
43.97%
76.29%
244.33%
458.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
7.98%
18.8%
40.28%
155.22%
176.63%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Sensei Biotherapeutics Inc
Sensei Biotherapeutics Inc
NA
NA
NA
-1.12
-0.42
-0.25
NA
2.33
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.71
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.32
30.32
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.73
49.73
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.07
31.07
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Sensei Biotherapeutics Inc
Sensei Biotherapeutics Inc
Buy
$15.6M
-96.62%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$55.7B
787.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$113.1B
233.31%
30.32
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$634.9B
458.71%
49.73
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$123.6B
176.63%
31.07
39.46%

Institutional Holdings

  • Newtyn Management LLC

    3.71%
  • Vanguard Group Inc

    2.29%
  • Renaissance Technologies Corp

    0.84%
  • Geode Capital Management, LLC

    0.54%
  • Bridgeway Capital Management, LLC

    0.45%
  • Bank of America Corp

    0.36%

Company Information

sensei biotherapeutics is an innovator in the field of next-generation cancer immunotherapies. sensei has pioneered a proprietary immuno-oncology technology platform, called spirit, to aid the immune system in the detection and elimination of cancer. the presence of subtle differences in antigen expression between cancer and normal is key to this process the spirit platform overcomes disabled immune recognition caused by cancer. the immune system has evolved to protect its host from foreign pathogens, effectively distinguishing healthy ‘self’ tissues from ‘non-self’. cancer is a unique challenge to the immune system. it arises from ‘self’ making immune recognition challenging, yet it is known to be altered. immune recognition of the subtle differences between ‘self’ and ‘non-self’ is key to effective cancer immunotherapy. headquartered in gaithersburg, md, sensei has built a unique and proprietary approach in-house and in collaboration with key academic collaborators at brown universit

Organization
Sensei Biotherapeutics Inc
Employees
27
CEO
Mr. John K. Celebi M.B.A.
Industry
Services

FAQs